- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Jackie Collins | Authors
Encouraging pCR Reported With Pembrolizumab Plus Chemo for Resectable Gastric, GEJ Adenocarcinoma
April 11, 2022
Patients with resectable gastric and gastroesophageal junction adenocarcinoma experienced good pathologic complete response with standard of care chemotherapy and perioperative/adjuvant pembrolizumab.
Olaparib Combo Yields Significant Non-Progression Rate for Endometrial Cancer
April 11, 2022
Patients with advanced or metastatic endometrial cancer experienced a significant non-progression rate following treatment with olaparib, metronomic cyclophosphamide, and metformin.
Adjuvant Pembrolizumab Plus Chemoradiotherapy Combo Will Be Investigated in High-Risk Endometrial Cancer
March 19, 2022
The ongoing KEYNOTE-B21 trial aims to determine if pembrolizumab plus adjuvant chemotherapy with or without radiotherapy will improve disease-free survival and overall survival in patients with newly diagnosed endometrial cancer.
Health-Related QOL Persists With Nivolumab Plus Cabozantinib Vs Sunitinib for First-Line RCC
February 20, 2022
Better health-related quality of life outcomes were associated with nivolumab and cabozantinib for advanced renal cell carcinoma vs sunitinib.
Greater Benefit With Trastuzumab Deruxtecan Vs T-DM1 Observed in Previously Treated HER2+ Breast Cancer
September 19, 2021
Data from the phase 3 DESTINY-Breast03 trial show trastuzumab deruxtecan bests trastuzumab emtansine in patients with previously treated HER2-positive metastatic breast cancer.
PFS Benefit Observed With Tislelizumab Plus Chemotherapy for Advanced Squamous NSCLC
September 08, 2021
Patients with stage IIIB and stage IV advanced squamous non–small cell lung cancer experienced a clinically significant improvement in progression-free survival with tislelizumab plus chemotherapy in the first-line setting compared with standard of care chemotherapy.